Acetyle Systeine and Contrast nephropathy
Phase 3
- Conditions
- ephropathy due to contrast agents.Postprocedural renal failure
- Registration Number
- IRCT201205305113N3
- Lead Sponsor
- ephrology Research Center, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 549
Inclusion Criteria
age more than 18; serum creatinine more than 1.5 mg/ dl ; not having AKI; not receiving nephrotoxine since 1 week before entering the study; signing the consent.
Exclusion criteria: the patients who undergo surgery in less than 1 week of contrast exposure; the patients who are in need for a nephrotoxine in less than five days after contrast exposure; the patients who need repeated contrast administration in less than five days of first exposure
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum creatinine. Timepoint: The second day and five days after contrast exposure. Method of measurement: Serum creatinine in plasma.
- Secondary Outcome Measures
Name Time Method Hypersensitivity to contrast. Timepoint: Immediately after exposure to contrast. Method of measurement: Physical conditions.